775 — CK Life Sciences Intl (Holdings) Income Statement
0.000.00%
- HK$8.07bn
- HK$13.60bn
- HK$5.52bn
- 13
- 24
- 72
- 27
Annual income statement for CK Life Sciences Intl (Holdings), fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,943 | 5,402 | 5,276 | 5,323 | 5,523 |
Cost of Revenue | |||||
Gross Profit | 1,407 | 1,630 | 1,626 | 1,637 | 1,693 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4,696 | 5,067 | 4,908 | 4,932 | 5,277 |
Operating Profit | 246 | 335 | 368 | 391 | 246 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 119 | 238 | 205 | 68.6 | -91.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 125 | 163 | 132 | 17.3 | -127 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 125 | 163 | 132 | 17.3 | -127 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 125 | 163 | 132 | 17.3 | -127 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.011 | 0.017 | 0.012 | -0.005 | -0.027 |
Dividends per Share |